Skip to main content
Year archive

Moberg Pharma — 2016 filings

All 70 regulatory filings released by Moberg Pharma (MOB) in 2016, sourced directly from the official regulator.

70 Filings
2016 Period
2016 filings (70)
Filing Released Lang
Moberg Pharma completes acquisition of DermoPlast from Prestige Brands
M&A Activity
2016-12-31 English
Moberg Pharma slutför förvärv av DermoPlast från Prestige Brands
M&A Activity
2016-12-31 Swedish
Change in number of shares and votes in Moberg Pharma
Declaration of Voting Results & Voting Rights Announcements
2016-12-30 English
Förändring av antalet aktier och röster i Moberg Pharma
Share Issue/Capital Change
2016-12-30 Swedish
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-12-28 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-27 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-23 English
Moberg Pharma completes divestment of PediaCare for $5.6 million
Regulatory Filings
2016-12-20 English
Moberg Pharma slutför avyttringen av PediaCare för 5,6 MUSD
M&A Activity
2016-12-20 Swedish
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-13 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-09 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-08 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-07 English
Moberg Pharma completes tap issue of SEK 215 million
Capital/Financing Update
2016-12-07 English
Moberg Pharma utökar sitt utestående obligationslån med 215 miljoner kronor
Capital/Financing Update
2016-12-07 Swedish
Moberg Pharma överväger ett förvärv av ett varumärke från Prestige Brands och utreder förutsättningarna för att genomföra en riktad emission av aktier
Share Issue/Capital Change
2016-12-06 Swedish
Moberg Pharma considers an acquisition of a brand from Prestige Brands and evaluates the preconditions for carrying out a directed new shares issue
Capital/Financing Update
2016-12-06 English
Moberg Pharma receives bondholders’ approval for increased flexibility in acquisition financing
Capital/Financing Update
2016-11-28 English
Moberg Pharma erhåller obligationsinnehavares godkännande avseende ökad flexibilitet för förvärvsfinansiering
Capital/Financing Update
2016-11-28 Swedish
Moberg Pharma avyttrar PediaCare för 5 miljoner USD
Report Publication Announcement
2016-11-24 Swedish
Moberg Pharma divests PediaCare for $5.0 million
M&A Activity
2016-11-24 English
Interim / Quarterly Report 2016
Interim / Quarterly Report 9M 2016
2016-11-08 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report 9M 2016
2016-11-08 English
Moberg Pharma summons bondholders’ meeting to gain additional flexibility in acquisition financing
Capital/Financing Update
2016-11-08 English
Moberg Pharma kallar till fordringshavarmöte för att få ökad flexibilitet för förvärvsfinansiering
Capital/Financing Update
2016-11-08 Swedish
MOBERG PHARMAS VALBEREDNING UTSEDD
Regulatory Filings
2016-11-04 Swedish
MOBERG PHARMA’S NOMINATION COMMITTEE APPOINTED
Board/Management Information
2016-11-04 English
Europeiskt patent beviljat för BUPI
Regulatory Filings
2016-10-19 Swedish
European Patent granted for BUPI
Regulatory Filings
2016-10-19 English
Moberg Pharma begins patient enrollment in North America and Europe in two Phase 3 studies of MOB-015 in onychomycosis
Regulatory Filings
2016-09-28 English
Inklusion av patienter påbörjad i Nordamerika och Europa i två fas 3 studier med MOB-015 mot nagelsvamp
Regulatory Filings
2016-09-28 Swedish
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-09-01 English
Moberg Pharma har beviljats tillstånd att starta fas 3-studie för MOB-015 i USA och Kanada
Regulatory Filings
2016-08-10 Swedish
Moberg Pharma announces approvals to start Phase 3 study for MOB-015 in U.S. and Canada
Regulatory Filings
2016-08-10 English
Earnings Release 2016
Earnings Release H1 2016
2016-08-09 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report H1 2016
2016-08-09 English
Moberg Pharma slutför förvärv av varumärken från Prestige Brands
Regulatory Filings
2016-07-08 Swedish
Moberg Pharma completes acquisition of U.S. OTC brands from Prestige Brands
M&A Activity
2016-07-08 English
Moberg Pharma completes tap issue of SEK 85m
Capital/Financing Update
2016-06-30 English
Moberg Pharma utökar sitt utestående obligationslån med 85 miljoner kronor
Capital/Financing Update
2016-06-30 Swedish
Moberg Pharma announces launch in Japan and provides market update for Kerasal Nail and Emtrix
Earnings Release FY 2016
2016-06-28 English
Moberg Pharma lanserar i Japan och ger en marknadsuppdatering för Kerasal Nail och Emtrix
Earnings Release FY 2016
2016-06-28 Swedish
Kommuniké från Moberg Pharmas årsstämma 2016
AGM Information
2016-05-18 Swedish
Bulletin from Moberg Pharma’s AGM 2016
AGM Information
2016-05-18 English
Earnings Release 2016
Earnings Release Q1 2016
2016-05-10 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-05-10 English
Notice of Annual General Meeting in Moberg Pharma AB (publ)
AGM Information
2016-04-19 English
Kallelse till årsstämma i Moberg Pharma AB (publ)
AGM Information
2016-04-19 Swedish
Annual Report 2015
Annual Report FY 2015
2016-04-19 Swedish
Annual Report 2015
Annual Report FY 2015
2016-04-19 English
Moberg Pharma slutför avyttringen av tre varumärken för 10,4 miljoner USD
M&A Activity
2016-04-04 Swedish
Moberg Pharma completes divestment of three brands for $10.4 million
Report Publication Announcement
2016-04-04 English
Moberg Pharma planerar att utveckla BUPI genom fas III
Earnings Release FY 2016
2016-03-22 Swedish
Moberg Pharma announces plans to develop BUPI through phase III
Regulatory Filings
2016-03-22 English
Moberg Pharma divests three brands for $10.0 million
M&A Activity
2016-03-07 English
Moberg Pharma avyttrar tre varumärken för 10 miljoner USD
M&A Activity
2016-03-07 Swedish
Moberg Pharma offentliggör obligationsprospekt och ansöker om inregistrering av sitt obligationslån vid Nasdaq Stockholm
Capital/Financing Update
2016-02-23 Swedish
Moberg Pharma publishes bond prospectus and applies for listing of its bond loan on Nasdaq Stockholm
Capital/Financing Update
2016-02-23 English
The Nomination Committee’s proposal to the Annual General Meeting 2016
AGM Information
2016-02-18 English
Valberedningens förslag till årsstämman 2016
AGM Information
2016-02-18 Swedish
Earnings Release 2015
Earnings Release FY 2015
2016-02-17 Swedish
Interim / Quarterly Report 2015
Interim / Quarterly Report FY 2015
2016-02-17 English
Moberg Pharma emitterar obligationslån om 300 miljoner kronor på den nordiska obligationsmarknaden för finansiering av tillväxt och förvärv
Capital/Financing Update
2016-01-25 Swedish
Moberg Pharma issues a bond loan in the amount of SEK 300 million on the Nordic bond market to finance growth and acquisitions
Capital/Financing Update
2016-01-25 English
Moberg Pharma is contemplating a potential bond issue and updates financial targets
Capital/Financing Update
2016-01-21 English
Moberg Pharma undersöker möjligheten att emittera ett obligationslån och uppdaterar finansiella mål
Capital/Financing Update
2016-01-21 Swedish
Moberg Pharma meddelar positiva fas II-resultat för BUPI
Regulatory Filings
2016-01-11 Swedish
Moberg Pharma announces positive phase II data for BUPI
Regulatory Filings
2016-01-11 English
Change in Moberg Pharma´s nomination committee
Board/Management Information
2016-01-08 English
Förändring i Moberg Pharmas valberedning
Board/Management Information
2016-01-08 Swedish